World Bulletin/News Desk
The World Health Organization has endorsed using HIV medicines among people who do not have the infection but are at high risk of getting it, and suggested that poor and wealthy countries alike set up pilot projects to better understand the benefits.
The United Nations agency made its suggestion on Friday, four days after U.S. regulators approved use of Gilead Sciences Inc's Truvada for people who are not infected but may engage in sexual activity with HIV-positive partners. The concept is known as pre-exposure prophylaxis (PrEP).
Truvada, which combines the anti-HIV drugs tenofovir and emtricitabine in one pill, is widely used to treat people already infected with the virus that causes AIDS. The medicine, which costs almost $14,000 a year in the United States, is the first treatment also approved for prevention.
"WHO is encouraging countries wishing to introduce PrEP to first establish small projects to help public health workers to better understand and realize its potential benefits," the agency said in a statement. It said appropriate HIV medicines should be given to those at high risk of infection.
"These could include men or transgender women who have sex with men," the group said.
WHO spokeswoman Sarah Russell said the agency could not recommend specific drugs for prevention, but she said, "It needs to be a drug like Truvada that has been developed for prevention purposes."
Russell said WHO expects Gilead to make Truvada available at a deeply discounted price in some poor countries.
"We believe Gilead will bring the price down to about $100 per year per person" in those countries, she said in an interview.
Gilead officials could not immediately be reached for comment.
WHO noted that an international study called Partners PrEP has shown that HIV medicines are highly effective at preventing the illness in men and women whose partners are infected.
That study, conducted in Kenya and Uganda and funded by the Bill & Melinda Gates Foundation, involved taking a daily tablet containing tenofovir or tenofovir in combination with emtricitabine.
The U.N. agency said it would evaluate the outcomes of the small projects, along with evolving scientific evidence, before issuing its own detailed guidelines next year on the use of HIV treatments for prevention.
WHO said it was important that people taking HIV drugs for prevention are HIV-negative because otherwise drug resistant forms of HIV could evolve. The agency said they should also continue using condoms and faithfully take their medicines on a daily basis.
MSF is discussing whether to shorten some Ebola assignments from their current duration of four to six weeks
The recent surge in cases, now numbering 32 since the start of October, has been focused in Riyadh and the western city of Taif
The meeting organized by ALBA, a bloc of leftist-governed countries, aims to coordinate a regional strategy on the prevention and control of Ebola
U.N. Secretary-General Ban Ki-moon has voiced his regret that health workers returning from Ebola-stricken countries in West Africa were quarantined.
In a research carried out in the U.S. reveals alarming findings about spending on illicit drugs -over $100 billion
The Township Owl Project takes juvenile birds rescued from perilous situations, such as when a building where they nested in is demolished, and gives them a new home and a new job
The three worst-hit countries of West Africa - Guinea, Liberia and Sierra Leone - account for the bulk, recording 4,912 deaths out of 10,114 cases
There are 883 confirmed cases of the deadly virus, out of which 319 people have died since 2012, the WHO says
WHO announces one million doses of Ebola vaccine to be produced in 2015
That pact would aim to improve on two decades of stuttering cooperation and rein in emissions of carbon dioxide blamed for a disruptive rise in temperatures
The World Health Organization last month urged the use of blood-derived products and serum from survivors.
Pentagon rapid-response Ebola medical team was scheduled to begin training at Fort Sam Houston in San Antonio, Texas
Extensively drug-resistant TB (XDR-TB), which is even more expensive and difficult to treat than multi drug-resistant (MDR-TB) strains, has now been reported in 100 countries around the world.
Device can be used in the field without special equipment, according to developers
The technique involved transplanting what are known as olfactory ensheathing cells into the patient's spinal cord and constructing a "nerve bridge" between two stumps of the damaged spinal column.
The meeting in Cuba is aimed at keeping Ebola at bay and it brings together senior officials from the ALBA bloc of nations